BOSTON, May 22 /PRNewswire-FirstCall/ -- PAREXEL International Corporation today announced that its technology subsidiary Perceptive Informatics, Inc. has been selected by Astellas Pharma Europe Limited (http://www.astellas.com/eu) to supply its clinical trial management system (CTMS).
In a review of 10 vendors, Astellas Pharma Europe Limited selected Perceptive's IMPACT(TM) software to replace all of its existing CTMS systems, integrate with the company's other system applications, and to enable Astellas Pharma Europe Limited more efficient management of its clinical development programs.
"Astellas Pharma Europe Limited has strategically chosen Perceptive's industry leading IMPACT software in order to provide a single and accurate source of clinical trial information and to provide a far higher level of system integration," said Senior Vice President, Research & Development, Astellas Pharma Europe. "Astellas Pharma Europe Limited's implementation of IMPACT is essential and will involve several key departments throughout our company, ranging from R&D, clinical research and pharmacovigilance to data operations and regulatory affairs."
"Astellas Pharma Europe's implementation of Perceptive's IMPACT suite of CTMS software will enable it to manage clinical trials with even greater effectiveness and efficiency. Perceptive's IMPACT software provides a comprehensive, robust and proven solution to centrally manage the complex information, processes and functions that support all aspects of clinical trials," said Todd A. Joron, Corporate Vice President and General Manager of Perceptive Informatics.
Perceptive Informatics is a leading provider of CTMS solutions and has the largest installation of CTMS users in the world. Perceptive's IMPACT software enables complete trial management and planning, activities monitoring, and clinical cost and supplies tracking. The IMPACT solution is the cornerstone of many clinical enterprises, interfacing with Interactive Voice and Web Response Systems (IVRS/IWRS), and electronic data capture (EDC) and data management applications, in addition to financial reporting. IMPACT allows for customized configuration, which assists companies in upgrading existing business processes and providing scalability for future growth. IMPACT provides accessibility to critical data, allowing companies to better manage clinical trials.
About Perceptive Informatics
Perceptive Informatics, Inc. combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive's portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(TM) solution is Perceptive's market-leading CTMS product with 25,000 users worldwide, and INITIATOR(TM) is a trial management product targeted to the needs of Phase I units. For more information about Perceptive Informatics, visit http://www.perceptive.com.
About PAREXEL
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 52 locations throughout 39 countries around the world, and has approximately 5,445 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets" and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the amendment or interpretation of Financial Accounting Standards Board Statement No. 123 (revised 2004), Share-Based Payment ("Statement 123R"), which could change the Company's current assessment of the effects of the adoption of Statement 123R on the acceleration of equity grants, the assumptions inherent in equity pricing models under Statement 123R and the final results of the closing of the Company's books for future financial periods; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2006 as filed with the SEC on May 9, 2006, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Media Contact: Jennifer Baird, Director of Public Relations PAREXEL International Tel: +1.781.434.4409 Email: Jennifer.Baird@PAREXEL.com
PAREXEL International CorporationCONTACT: Jennifer Baird, Director of Public Relations at PAREXELInternational, +1-781-434-4409, Jennifer.Baird@PAREXEL.com
